Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × GI Cancers × 1 year × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 260 Breast Neoplasms 173 Neoplasms 170 Colorectal Neoplasms 158 Neoplasm Metastasis 125 Ovarian Neoplasms 119 Melanoma 119 Leukemia, Myeloid, Acute 119 Recurrence 115 Prostatic Neoplasms 115 Pancreatic Neoplasms 112 Multiple Myeloma 104 Lung Neoplasms 98 Stomach Neoplasms 94 Squamous Cell Carcinoma of Head and Neck 89 Triple Negative Breast Neoplasms 86 Lymphoma, Non-Hodgkin 80 Lymphoma 80 Glioblastoma 79 Precursor Cell Lymphoblastic Leukemia-Lymphoma 67 Lymphoma, Large B-Cell, Diffuse 67 Carcinoma, Renal Cell 66 Endometrial Neoplasms 59 Carcinoma, Hepatocellular 58 Advanced Solid Tumor 56 Uterine Cervical Neoplasms 54 Myelodysplastic Syndromes 54 Sarcoma 53 Leukemia 53 Small Cell Lung Carcinoma 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07216560 2026-01-15

First-in-human Study of 7MW4911 in GI Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2 Recruiting

GI Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡